Thin
1 / 1
Triptorelin is a synthetic decapeptide gonadotropin-releasing hormone (GnRH) agonist that works by acting continuously on pituitary GnRH receptors, initially stimulating and ultimately inhibiting the secretion of gonadotropins (LH, FSH), thereby reducing sex hormone (testosterone, estrogen) levels. Clinically, it is commonly used in acetate or papoate form, with sustained-release formulations (such as 1, 3, or 6-month injections) to achieve continuous action.
Triptorelin is a synthetic decapeptide GnRH agonist. It works by continuously acting on pituitary GnRH receptors, which initially stimulates and ultimately inhibits the secretion of gonadotropins, thereby effectively reducing sex hormone levels like testosterone and estrogen.
Clinically, it is commonly used in acetate or papoate form through sustained-release formulations. These are typically administered as 1, 3, or 6-month injections to achieve a continuous therapeutic effect.
In oncology, it serves as a first-line endocrine therapy for advanced or high-risk prostate cancer by lowering testosterone to castration levels. It is also used in premenopausal hormone receptor-positive breast cancer for ovarian function suppression.
It is used to relieve pain from endometriosis, shrink uterine fibroids prior to surgery, inhibit central precocious puberty, and for pituitary downregulation before controlled ovarian hyperstimulation in assisted reproductive technology (ART).
Future developments are heavily focused on long-acting formulations to improve patient compliance, utilizing sustained-release technologies like microspheres and implants, and exploring combination therapies with novel targeted drugs.
The primary challenges include managing side effects such as decreased bone density, hot flashes, and cardiovascular risks. Additionally, addressing drug resistance in patients who progress to castration-resistant prostate cancer (CRPC) requires ongoing exploration of sequential therapies.
